Drug
Nadofaragene Firadenovec
Nadofaragene Firadenovec: highest development phase Phase 3, developed by Ferring Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ferring Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nadofaragene Firadenovec NCT06545955 | Phase 3 | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ |
| Nadofaragene Firadenovec NCT06510374 | Phase 3 | Intermediate Risk Non-Muscle Invasive Bladder Cancer |
Latest
No recent events.
Follow Nadofaragene Firadenovec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.